These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35378715)

  • 1. Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate.
    Kjerengtroen S; Chauv S; Hickman AW; Collingridge DS; Fontaine GV
    J Thromb Thrombolysis; 2022 Aug; 54(2):268-275. PubMed ID: 35378715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate.
    Jansma B; Montgomery J; Dietrich S; Mixon MA; Peksa GD; Faine B
    Ann Pharmacother; 2020 Nov; 54(11):1090-1095. PubMed ID: 32418445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal.
    Klein L; Peters J; Miner J; Gorlin J
    Am J Emerg Med; 2015 Sep; 33(9):1213-8. PubMed ID: 26143315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of fixed versus variable dosing of 4-factor prothrombin complex concentrate for emergent warfarin reversal.
    Stoecker Z; Van Amber B; Woster C; Isenberger K; Peterson M; Rupp P; Chrenka E; Dries D
    Am J Emerg Med; 2021 Oct; 48():282-287. PubMed ID: 34022636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed dose 4-factor prothrombin complex concentrate for the emergent reversal of warfarin: a retrospective analysis.
    Astrup G; Sarangarm P; Burnett A
    J Thromb Thrombolysis; 2018 Feb; 45(2):300-305. PubMed ID: 29164374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of Warfarin-Associated Major Hemorrhage: Activated Prothrombin Complex Concentrate versus 4-Factor Prothrombin Complex Concentrate.
    Peksa GD; Mokszycki RK; Rech MA; Maynard B; Panos NG; Sweis RT; DeMott JM
    Thromb Haemost; 2020 Feb; 120(2):207-215. PubMed ID: 31837652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
    Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
    Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
    Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
    J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Factor Prothrombin Complex Concentrate Dosing Strategies: A Retrospective Evaluation.
    Reachi B; Negrelli J; Rapier M; Hickman A
    J Pharm Pract; 2024 Apr; 37(2):287-295. PubMed ID: 36206169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal in Patients with Intracranial Hemorrhage.
    Scott R; Kersten B; Basior J; Nadler M
    J Emerg Med; 2018 Jun; 54(6):861-866. PubMed ID: 29510892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.
    Zemrak W; Manuel F; Smith KE; Rolfe S; Hayes T; Trowbridge RL; Carlone B; Seder D
    J Thromb Thrombolysis; 2019 Feb; 47(2):263-271. PubMed ID: 30443817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal.
    McMahon C; Halfpap J; Zhao Q; Bienvenida A; Rose AE
    Ann Pharmacother; 2021 Oct; 55(10):1230-1235. PubMed ID: 33522256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 3 Different Prothrombin Complex Concentrate Regimens for Emergent Warfarin Reversal: PCCWaR Study.
    Dietrich SK; Rowe S; Cocchio CA; Harmon AJ; Nerenberg SF; Blankenship PS
    Ann Pharmacother; 2021 Aug; 55(8):980-987. PubMed ID: 33305592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified version of the American College of Cardiology's recommendation for low-dose prothrombin complex concentrate is effective for warfarin reversal.
    Gilbert BW; Morton L; Huffman JB; Roemer K; Potter A; Cassidy CD; Vasquez DG
    Am J Emerg Med; 2020 Apr; 38(4):806-809. PubMed ID: 31864879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity increases risk of anticoagulation reversal failure with prothrombin complex concentrate in those with intracranial hemorrhage.
    Chu C; Tokumaru S; Izumi K; Nakagawa K
    Int J Neurosci; 2016; 126(1):62-6. PubMed ID: 25430740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
    Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
    Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
    Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
    Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated Prothrombin Complex Concentrate versus Plasma for Reversal of Warfarin-Associated Hemorrhage.
    Rowe AS; Mahbubani PS; Bucklin MH; Clark CT; Hamilton LA
    Pharmacotherapy; 2016 Nov; 36(11):1132-1137. PubMed ID: 27726162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experiences with an activated 4-factor prothrombin complex concentrate (FEIBA) for reversal of warfarin-related bleeding.
    Stewart WS; Pettit H
    Am J Emerg Med; 2013 Aug; 31(8):1251-4. PubMed ID: 23763937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.